NYSE$ELV
Elevance Health Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Anthem reported strong financial performance in Q3 2021, with revenue and medical enrollment increasing.
Anthem, Inc. reported a strong third quarter in 2021, with a 16.0% increase in operating revenue to $35.5 billion and a rise in medical enrollment by 2.4 million members year over year to 45.1 million members. GAAP net income was $6.13 per share, and adjusted net income was $6.79 per share. The company also raised its full-year adjusted net income outlook.
- GAAP net income was $6.13 per share, including net negative adjustment items of $0.66 per share; adjusted net income was $6.79 per share.
- Operating revenue grew by 16.0% over the prior year quarter to $35.5 billion, or 17.5% adjusted for the repeal of the health insurance tax.
- Medical enrollment increased by 2.4 million members year over year and 730 thousand members in the third quarter to 45.1 million members.
- The company is raising full year adjusted net income outlook from greater than $25.50 per share to greater than $25.85 per share.
Headline financials
Revenue & EPS history
Elevance Health · Revenue · Quarterly
$35.8B
Revenue by segment
Elevance Health · $36.7B total across 1 segment · Q3 2023
- Health Benefits$36.7B—100.0%
Forward guidance
Anthem expects GAAP net income to be greater than $24.70 per share and adjusted net income to be greater than $25.85 per share for the full year 2021. Operating cash flow is expected to be greater than $6.0 billion, and investment income is expected to be approximately $1.2 billion.
Tailwinds
- GAAP net income is expected to be greater than $24.70 per share.
- Adjusted net income is expected to be greater than $25.85 per share.
- Operating cash flow is expected to be greater than $6.0 billion.
- Investment income is expected to be approximately $1.2 billion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+2.4%
Avg return
30 days after
54%
25 / 46 earnings
Positive
+11.1%
Q4 2018
Best reaction
-15.0%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.3% | +8.5% | +20.3% | |
| Q4 2025 | +5.1% | +5.9% | -0.9% | |
| Q3 2025 | -1.1% | -3.3% | -11.3% | |
| Q2 2025 | +0.3% | +6.0% | +5.9% | |
| Q1 2025 | +2.1% | +3.7% | -5.5% | |
| Q4 2024 | +2.9% | +3.8% | -1.4% | |
| Q3 2024 | -15.0% | -15.5% | -19.4% | |
| Q2 2024 | -8.7% | -8.9% | -1.7% | |
| Q1 2024 | +4.1% | +4.7% | +7.6% | |
| Q4 2023 | +1.8% | +3.0% | +8.9% | |
| Q3 2023 | -0.6% | -3.0% | -0.6% | |
| Q2 2023 | +7.2% | +6.2% | +4.3% | |
| Q1 2023 | -5.8% | -4.2% | -5.2% | |
| Q4 2022 | +3.6% | +2.2% | -0.1% | |
| Q3 2022 | +2.0% | +10.1% | +3.6% | |
| Q2 2022 | -7.6% | -5.3% | +1.2% | |
| Q1 2022 | +1.1% | -2.0% | -4.7% | |
| Q4 2021 | -0.8% | +0.4% | +3.3% | |
| Q3 2021 | +9.3% | +10.4% | +5.5% | |
| Q2 2021 | -1.4% | -2.9% | -3.1% | |
| Q1 2021 | -0.5% | -1.1% | +3.7% | |
| Q4 2020 | -3.8% | -6.4% | -3.0% | |
| Q3 2020 | -8.6% | -6.9% | +4.7% | |
| Q2 2020 | +4.5% | +2.1% | +4.5% | |
| Q1 2020 | +4.7% | +1.0% | +9.7% | |
| Q4 2019 | -8.4% | -8.2% | -11.4% | |
| Q3 2019 | -0.3% | +2.9% | +12.1% | |
| Q2 2019 | -2.9% | -1.4% | -13.9% | |
| Q1 2019 | +2.1% | +6.2% | +10.6% | |
| Q4 2018 | +11.1% | +11.6% | +12.8% | |
| Q3 2018 | +0.2% | +1.4% | +9.3% | |
| Q2 2018 | +0.4% | +2.5% | +7.8% | |
| Q1 2018 | +5.3% | +4.9% | +3.3% | |
| Q4 2017 | +0.2% | -5.3% | -4.3% | |
| Q3 2017 | +6.0% | +7.3% | +12.9% | |
| Q2 2017 | -3.7% | -2.3% | +1.1% | |
| Q1 2017 | +3.4% | +3.9% | +6.2% | |
| Q4 2016 | +2.3% | +1.7% | +7.7% | |
| Q3 2016 | +2.2% | +5.2% | +23.6% | |
| Q2 2016 | -3.4% | -7.3% | -9.2% | |
| Q1 2016 | -2.1% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | -2.1% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2009 | — | — | — | |
| Q1 2010 | — | — | — | |
| Q4 2007 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q3 2009 | — | — | — | |
| Q3 2008 | — | — | — | |
| Q4 2008 | — | — | — | |
| Q2 2009 | — | — | — | |
| Q2 2008 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro